SEARCH PLATELETNEWS.ORG
Faculty

Peter B. Berger, MD

Co-Chair

Glenn N. Levine, MD

Co-Chair
Poll
question goes here

Educational Links
You need to upgrade your Flash Player
Dynamic Slide Library Index



Clinical Guidelines

NSTE-ACS
Recommendations for Oral Antiplatelet Drugs: European Guidelines

NSTEMI
Recommendations for Oral Antiplatelet Drugs: European Guidelines
Timing and Dose of GP IIb/IIIa Inhibitors and Clopidogrel: American Guidelines
Timing and Dose of GP IIb/IIIa Inhibitors and Clopidogrel: American Guidelines (cont’d)

PCI
 


Clinical Trials

A-F
Antithrombotic Trialists’ Collaboration 2002: Indirect Comparisons Effect of ASA Doses on Vascular Events in High-Risk Patients
ACUITY: Composite Ischemia Endpoint
CURE: Primary Endpoint—MI/Stroke/Cardiovascular Death
CURE: Benefit of Clopidogrel Therapy at Various Time Intervals
CURE: Long-Term Results by Management Strategy
CURE: Bleeding Episodes Through Follow-Up
ALBION: Dose Effect With Clopidogrel in ACS
CLARITY-TIMI 28: Primary Endpoint: Occluded Artery (or Death/MI through Angio/HD)
CLARITY-TIMI 28: Cardiac Death, Myocardial Infarction, Recurrent Ischemia --> Urgent Revascularization
COMMIT: Effects of Clopidogrel on Death, Re-Myocardial Infarction, or Stroke
COMMIT: Effect of Clopidogrel on Death in Hospital
COMMIT: Effects of Clopidogrel on Death, Re-Myocardial Infarction, or Stroke by Delay and Fibrinolytic
Bivalirudin Angioplasty Trial (BAT) and Final Analysis
REPLACE 2 (PCI) and ACUITY (PCI Patients Only)
ACUITY: Death, MI, Target Vessel Revascularization
CV Death, MI, or Stroke Following PCI
Frequency Distribution of Platelet Inhibition After Cessation of Daily Clopidogrel Therapy
Adjustment of Clopidogrel Loading Dose Using the VASP Index: Effects on MACE

G-L
ISAR-REACT: Results, 30 Days
ISAR-REACT: Death or MI, 12 Months
ISAR-SWEET: Adverse Events, 30 Days
ISAR-REACT 2: Efficacy Analysis
HORIZONS AMI: Impact of Clopidogrel Loading Dose on Efficacy of Bivalirudin

M-R
PCI-CURE: Early and Long-Term Clopidogrel in PCI Patients
REPLACE-1: Treated Population
REPLACE-2: Triple Ischemic Endpoint
REPLACE 2:Endpoints, 30 Days
REPLACE 2 (PCI) and ACUITY (PCI Patients Only)
PCI-CLARITY Meta-Analysis of Clopidogrel Pretreatment CV Death or MI After PCI, 30 Days
CV Death, MI, or Stroke Following PCI
Persistent Platelet Inhibition Variability With Increasing Clopidogrel Loading Dose
Out-of-Hospital 6-Month Post-PCI Outcomes Stratified by Reactivity in Patients on Consistent Clopidogrel Therapy

S-Z
Time Course of Platelet Inhibition After Different Clopidogrel Loading Doses
Time Course of Platelet Recovery After a Single Clopidogrel 600-mg Dose
Triple Antiplatelet Therapy in Patients With Acute MI Undergoing PCI
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Subgroup Analysis of Antiplatelet Therapy Effect on Thrombosis
 


Hyporesponsiveness
 


Pharmacologic Treatment

Aspirin
Antithrombotic Trialists’ Collaboration 2002: Indirect Comparisons Effect of ASA Doses on Vascular Events in High-Risk Patients
What Is the Most Effective Dose of Aspirin?
CURE: Primary Endpoint—MI/Stroke/Cardiovascular Death
CURE: Benefit of Clopidogrel Therapy at Various Time Intervals
PCI-CURE: Early and Long-Term Clopidogrel in PCI Patients
CURE: Bleeding Episodes Through Follow-Up
COMMIT: Effects of Clopidogrel on Death, Re-Myocardial Infarction, or Stroke
COMMIT: Effect of Clopidogrel on Death in Hospital
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Subgroup Analysis of Antiplatelet Therapy Effect on Thrombosis

Thienopyridines
Timing and Dose of GP IIb/IIIa Inhibitors and Clopidogrel: American Guidelines
Timing and Dose of GP IIb/IIIa Inhibitors and Clopidogrel: American Guidelines (cont’d)
CURE: Primary Endpoint—MI/Stroke/Cardiovascular Death
CURE: Benefit of Clopidogrel Therapy at Various Time Intervals
CURE: Long-Term Results by Management Strategy
PCI-CURE: Early and Long-Term Clopidogrel in PCI Patients
CURE: Bleeding Episodes Through Follow-Up
ALBION: Dose Effect With Clopidogrel in ACS
CLARITY-TIMI 28: Primary Endpoint: Occluded Artery (or Death/MI through Angio/HD)
CLARITY-TIMI 28: Cardiac Death, Myocardial Infarction, Recurrent Ischemia --> Urgent Revascularization
COMMIT: Effects of Clopidogrel on Death, Re-Myocardial Infarction, or Stroke
COMMIT: Effect of Clopidogrel on Death in Hospital
COMMIT: Effects of Clopidogrel on Death, Re-Myocardial Infarction, or Stroke by Delay and Fibrinolytic
PCI-CLARITY Meta-Analysis of Clopidogrel Pretreatment CV Death or MI After PCI, 30 Days
CV Death, MI, or Stroke Following PCI
ISAR-REACT: Results, 30 Days
ISAR-REACT: Death or MI, 12 Months
ISAR-SWEET: Adverse Events, 30 Days
ISAR-REACT 2: Efficacy Analysis
Time Course of Platelet Inhibition After Different Clopidogrel Loading Doses
Persistent Platelet Inhibition Variability With Increasing Clopidogrel Loading Dose
Out-of-Hospital 6-Month Post-PCI Outcomes Stratified by Reactivity in Patients on Consistent Clopidogrel Therapy
Frequency Distribution of Platelet Inhibition After Cessation of Daily Clopidogrel Therapy
Time Course of Platelet Recovery After a Single Clopidogrel 600-mg Dose
Triple Antiplatelet Therapy in Patients With Acute MI Undergoing PCI
HORIZONS AMI: Impact of Clopidogrel Loading Dose on Efficacy of Bivalirudin
Adjustment of Clopidogrel Loading Dose Using the VASP Index: Effects on MACE
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Subgroup Analysis of Antiplatelet Therapy Effect on Thrombosis

GP IIb/IIIa inhibitors
GP IIb/IIIa Inhibitor Overview: 30-Day Death and MI
Timing and Dose of GP IIb/IIIa Inhibitors and Clopidogrel: American Guidelines
Timing and Dose of GP IIb/IIIa Inhibitors and Clopidogrel: American Guidelines (cont’d)
ACUITY: Composite Ischemia Endpoint
REPLACE-1: Treated Population
REPLACE-2: Triple Ischemic Endpoint
REPLACE 2:Endpoints, 30 Days
REPLACE 2 (PCI) and ACUITY (PCI Patients Only)
ACUITY: Death, MI, Target Vessel Revascularization
ISAR-REACT: Results, 30 Days
ISAR-REACT: Death or MI, 12 Months
ISAR-SWEET: Adverse Events, 30 Days
ISAR-REACT 2: Efficacy Analysis
HORIZONS AMI: Impact of Clopidogrel Loading Dose on Efficacy of Bivalirudin

Antithrombotic Therapies
ACUITY: Composite Ischemia Endpoint
Bivalirudin Angioplasty Trial (BAT) and Final Analysis
REPLACE-1: Treated Population
REPLACE-2: Triple Ischemic Endpoint
REPLACE 2:Endpoints, 30 Days
REPLACE 2 (PCI) and ACUITY (PCI Patients Only)
ACUITY: Death, MI, Target Vessel Revascularization
ISAR-REACT 2: Efficacy Analysis
HORIZONS AMI: Impact of Clopidogrel Loading Dose on Efficacy of Bivalirudin

Novel agents
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Subgroup Analysis of Antiplatelet Therapy Effect on Thrombosis

Dosing
CURE: Primary Endpoint—MI/Stroke/Cardiovascular Death
 


Platelet Function Testing

Inhibition
Time Course of Platelet Inhibition After Different Clopidogrel Loading Doses
Persistent Platelet Inhibition Variability With Increasing Clopidogrel Loading Dose
Frequency Distribution of Platelet Inhibition After Cessation of Daily Clopidogrel Therapy
Time Course of Platelet Recovery After a Single Clopidogrel 600-mg Dose

Hyporesponsiveness
Out-of-Hospital 6-Month Post-PCI Outcomes Stratified by Reactivity in Patients on Consistent Clopidogrel Therapy

Platelet Reactivity
Adjustment of Clopidogrel Loading Dose Using the VASP Index: Effects on MACE
 


Platelet Role in Thrombosis
 


Stents

Bare metal
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Subgroup Analysis of Antiplatelet Therapy Effect on Thrombosis

Drug-eluting
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Intensive Antiplatelet Therapy and Rates of Thrombosis
TRITON-TIMI 38: Subgroup Analysis of Antiplatelet Therapy Effect on Thrombosis